Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prolactin and endocrine therapy resistance in breast cancer: The next potential hope for breast cancer treatment.

Journal of cellular and molecular medicine - 1 Nov 2021

Li Yuan, Kong Xiangyi, Xuan Lixue, Wang Zhongzhao, Huang Yen-Hua

Abstract excerpt

Breast cancer, a hormone-dependent tumour, generally includes four molecular subtypes (luminal A, luminal B, HER2 enriched and triple-negative) based on oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2. Multiple hormones in the body regulate the development of breast cancer. Endocrine therapy is one of the primary treatments for hormone-receptor-positive breast cancer, but...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Clinical Decision-Making

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Management

Share to Neoplastic Stem Cells

Share to Prolactin

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Source

Open in PubMed Open full text

Identifiers

PMID: 34651424
DOI: 10.1111/jcmm.16946
PMCID: PMC8581311

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prolactin and endocrine therapy resistance in breast cancer: The next potential hope for breast cancer treatment.PMID 34651424Read ↗

Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential TherapySemantic proximity Read ↗

Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasivenessSemantic proximity Read ↗

Breast Cancer and Prolactin – New Mechanisms and ModelsSemantic proximity Read ↗

Prolactin: The New Biology of an Old HormoneSemantic proximity Read ↗

Recent Findings on Hyperprolactinemia and its Pathological Implications: A Literature ReviewSemantic proximity Read ↗

Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy ResistanceSemantic proximity Read ↗

A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.Semantic proximity Read ↗

Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer.Semantic proximity Read ↗

Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: An updateSemantic proximity Read ↗

New concepts in prolactin biology.Semantic proximity Read ↗

The Role of Prolactin in Mammary CarcinomaSemantic proximity Read ↗

Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.